Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine added to risperidone for autism spectrum disorder
IRCT20190714044199N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of acetylcysteine and risperidone in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Clinical response in autism spectrum disorder, Childhood Autism Rating Scale score and 1 more. Started Aug 2019; status: completed.
02
Drugs
acetylcysteinerisperidone
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20190714044199N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190714044199N1.